Introduction
Follicular lymphoma, non-Hodgkin lymphoma, NHL
FOLLICULAR LYMPHOMA, NON-HODGKIN LYMPHOMA, NHL
Follicular lymphoma (FL), an indolent form of non-Hodgkin lymphoma (NHL), is considered incurable in most patients due to its typically relapsing-remitting pattern [Cellular therapies, specifically anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies, have demonstrated promising results in clinical trials. Based on the results from the ZUMA-5 trial, axicabtagene ciloleucel was approved by the US FDA for patients with r/r FL after ≥ 2 prior lines of therapy [Currently, no commercial CAR-T therapies are approved for indolent r/r FL in Japan and this highlights the need for clinical efficacy and safety data with CAR-T therapies in Japanese patients. Here, we report the results of the Japanese subset analysis from the ELARA trial investigating the efficacy, safety, and cellular kinetics of tisagenlecleucel in adult patients with r/r FL who received ≥ 2 prior lines of therapy.